West Paces Advisors’s CRISPR Therapeutics CRSP Stock Holding History

West Paces Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-85	Closed	-$2.89K	–	288
2025 Q1	$2.89K	Hold	85	–	–	﹤0.01%	415
2024 Q4	$3.35K	Hold	85	–	–	﹤0.01%	409
2024 Q3	$3.99K	Hold	85	–	–	﹤0.01%	395
2024 Q2	$4.59K	Hold	85	–	–	﹤0.01%	394
2024 Q1	$5.79K	Hold	85	–	–	﹤0.01%	395
2023 Q4	$5.32K	Hold	85	–	–	﹤0.01%	405
2023 Q3	$3.86K	Hold	85	–	–	﹤0.01%	403
2023 Q2	$4.77K	Hold	85	–	–	﹤0.01%	424
2023 Q1	$3.85K	Hold	85	–	–	﹤0.01%	441
2022 Q4	$3.46K	Buy	85 +50	+143%	+$2.65K	﹤0.01%	415
2022 Q3	$2.29K	Hold	35	–	–	﹤0.01%	428
2022 Q2	$2.13K	Hold	35	–	–	﹤0.01%	489
2022 Q1	$2.2K	Hold	35	–	–	﹤0.01%	481
2021 Q4	$2.65K	Buy	+35	New	+$3.06K	﹤0.01%	496

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

West Paces Advisors's CRSP Position: Q2 2025 in Review

West Paces Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 85 shares — an estimated $2.89K sold.

West Paces Advisors first reported a position in CRSP in Q4 2021 and held it in 14 quarters. The position peaked at $5.79K in Q1 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

West Paces Advisors reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
West Paces Advisors sold 85 CRISPR Therapeutics shares in Q2 2025, an estimated $2.89K.
West Paces Advisors first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 14 quarters.
West Paces Advisors's CRISPR Therapeutics position peaked at $5.79K in Q1 2024.
433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on West Paces Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.